Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial
Primary resultResult — go to the resultRisk difference 2.33 percentage points 95% CI −2.07 to 6.74Authors' conclusion
In patients with diabetes and multivessel disease undergoing PCI, ticagrelor was not noninferior to prasugrel for the reduction of primary outcome at 1 year of follow-up.
Study context
- Population
- Patients with DM and multivessel CAD undergoing percutaneous coronary intervention (PCI)randomized
- Participants
- 1,800 patients
- Comparison
- Ticagrelor vs prasugrel, each with low-dose aspirin
- Primary endpoint
- Composite of:
- Death
- Nonfatal MI
- Stroke
- BARC major bleeding (non-inferiority margin 5%)
- Follow-up
- 1 year
Methodological detailsinvestigator-initiated, prospective, open-label, multicenter, 2 × 2 factorial, non-inferiority, 66 clinical sites
- Investigator-initiated
- Prospective
- Open-label
- Multicenter
- 2 × 2 factorial
- Non-inferiority
- 66 clinical sites
Primary result
As reported in the abstract
Risk difference
2.33 percentage points
95% CI −2.07 to 6.74
P = 0.84 for non-inferiority
Events by treatment group
Ticagrelor vs Prasugrel
risk difference 2.33 percentage points (95% CI −2.07 to 6.74); P for non-inferiority = 0.84
Non-inferiority margin 5 as printed, not drawn
Further findings
Death, MI or stroke · not statistically significant
P = 0.30
Safety
Major bleeding · not statistically significant
P = 0.19
Original publication
Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial. JAMA Cardiol. Published 1 April 2026. doi:10.
Summarised from the published abstract; every number is checked against it